Skip to content
MarketScale
‹ Back to IndustriesHealthcare

The Future of Healthcare Is Already Here: Dr. Geoffrey Rutledge on Virtual Care, AI, and Access

The article discusses the advancements in healthcare with a focus on virtual care, AI, and access, featuring insights from Dr. Geoffrey Rutledge. It explores how these technologies are shaping the future of healthcare delivery. The conversation touches upon the impact on patient care and the potential for improved healthcare accessibility.

This story was produced through MarketScale. See how Healthcare teams put it to work with Executive Thought Leadership.

Promoted content from I Don't Care on MarketScale.

By Kevin Stevenson ·
Share

Key takeaways

01

Virtual care and AI are transforming healthcare.

02

These technologies enhance patient accessibility and care.

03

Healthcare delivery is continuously evolving with new innovations.

Dr. Geoffrey Rutledge has spent his career at the intersection of medicine and technology, from helping build the early infrastructure that became WebMD to cofounding HealthTap, a virtual primary care platform he has led as chief medical officer for sixteen years. His background spans Stanford medical informatics, NIH-supported academic research, and hands-on clinical practice. In a recent conversation on the podcast "I Don't Care" with host Dr. Kevin Stevenson, Rutledge made a case that challenges the conventional wisdom around virtual care: that a doctor can actually build a deeper relationship with a patient through a screen than across an exam table.

That counterintuitive claim sits at the center of how HealthTap has reshaped its model over the past several years. Rutledge described a shift in his own thinking that began as he watched physicians on the platform connect with patients they had never met in person. What he observed contradicted his original assumption that virtual care would always need an in-person foundation to be meaningful.

"When you take away the office and the computer and the nurse in the hall and the examining room behind you and you just have the connection with the patient, you connect with them in ways that are very powerful and meaningful, and more sometimes than happens in the office where there's so many distractions. — Dr. Geoffrey Rutledge, CMO, HealthTap"

Access is not just a rural problem

Rutledge pushed back on the idea that virtual care is primarily a solution for patients in remote or rural areas. He pointed to congested urban markets where appointment wait times stretch for months, where patients with young children cannot leave home due to daycare constraints, and where mobility limitations make even a short office visit a significant burden. The transactional model that defined early telehealth, where a patient logs on, gets a prescription or a diagnosis, and disconnects, addressed some of those barriers but left most of the value of primary care untouched. Rutledge argued that the real opportunity lies in continuity: a virtual panel of patients who see the same physician repeatedly and develop a relationship over time, with the platform supporting reminders, follow-through on recommendations, and preventive care conversations that rarely fit inside a fifteen-minute office visit.

He was direct about what the industry got wrong in the early years. Businesses chasing per-transaction revenue optimized for volume rather than care quality, and the pressure to move patients through quickly is not unique to virtual care. Rutledge described the same dynamic playing out in corporate primary care practices, where physician productivity metrics push doctors to order tests as a way to hand off the decision rather than spend more time on the history. His own mentor's instruction stayed with him: if you have finished the history and still do not know what the patient has, you have not finished the history.

What the pandemic revealed, and what providers forgot

COVID-19 forced widespread adoption of virtual visits, but Rutledge was measured about what that experiment actually proved. Patients discovered that virtual care could meet many of their needs and found it more convenient. Physicians, however, largely reverted to office-based practice once restrictions lifted, partly because that is where their training and professional identity are centered, and partly because compensation structures continue to reward in-person encounters. The lesson that stuck for Rutledge is not that virtual care should replace in-person medicine, but that a well-designed hybrid model would route patients to the right setting from the start. A primary care physician who knows a patient can determine whether a symptom warrants an emergency visit, a specialist referral, or a conversation. Without that expert filter, patients self-select, often ending up in the wrong place and generating unnecessary cost.

"If you can do what you need virtually, it really should be done virtually because it's inefficient and unnecessary and inconvenient to do it any other way. — Dr. Geoffrey Rutledge, CMO, HealthTap"

AI as a tool, not a replacement

On the question of artificial intelligence, Rutledge drew a clear line between what large language models can do today and what physicians still must do. He acknowledged that LLMs have become capable of answering informational health questions with reasonable accuracy, something that required a curated network of 100,000 volunteer physicians when HealthTap launched its original Q&A service in 2010. But answering the question of what a specific patient should do remains a clinical judgment that requires a doctor who knows the patient. At HealthTap, AI supports that physician rather than standing in for one: streamlining documentation, surfacing relevant clinical information, and reducing administrative friction so that the first virtual visit can run a full thirty minutes focused on the patient. Rutledge sees the next five years as a period of rapid capability growth, but he is equally focused on closing the adoption gap for technology that already works. In his view, the infrastructure for better primary care exists. The harder problem is changing the systems and incentives that keep it from reaching patients at scale.

I Don't Care

Part of this channel

I Don't Care

Candid healthcare leadership conversations with Kevin Stevenson

Visit the channel →

About the author

KS
Kevin Stevenson

Healthcare: are you visible to AI?

Before they reach out, Healthcare buyers ask AI engines which vendors to trust. See how AI describes your company today, and where competitors show up instead.

Free workspace

You just read one expert. Imagine publishing your whole team.

This article was produced through MarketScale. Create a free workspace and turn your own team's expertise into articles, video, and social posts. No credit card, no demo required.

NPS +73 · 1,000+ creators · 38+ countries

What you get, free

Your own MarketScale Studio workspace
One video edit a month, on us
AI writing, editing, and publishing tools
In-platform coaching to learn the system

More Healthcare Insights

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Gene therapies, early detection, and GLP-1 drugs are reshaping enterprise healthcare procurement

Recent advancements in healthcare, including gene therapies, early detection methods, and GLP-1 drugs, are influencing enterprise healthcare procurement strategies. These innovations are impacting benefit plan adjustments and procurement decision-making processes. The healthcare industry is experiencing a notable shift due to FDA-cleared treatments and predictive diagnostics.

  • 01Gene therapies and early detection methods are transforming healthcare procurement.
  • 02FDA-cleared treatments are prompting shifts in benefit plans.
  • 03Advancements are accelerating decision-making in healthcare procurement.

Jul 14, 2026

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

FDA clears UpDoc's LLM diabetes app, grants Aidoc breakthrough status as clinical AI crosses new regulatory thresholds

UpDoc has received FDA clearance for its LLM-driven diabetes management app, while Aidoc has been granted breakthrough device status for its AI-drafted radiology reports. This marks a significant milestone as clinical AI applications continue to gain regulatory approval and recognition. The advancements showcase the potential of AI in improving healthcare management and diagnostic processes.

  • 01UpDoc's diabetes management app receives FDA clearance.
  • 02Aidoc achieves breakthrough device status for AI radiology reports.
  • 03Regulatory milestones highlight AI's growing role in healthcare.

Jul 13, 2026

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

Cedars-Sinai's CDAIO on healthcare AI's second wave: workforce transformation, not just productivity

The chief data and AI officer at Cedars-Sinai discusses the evolving role of AI in healthcare. While the first wave of AI focused on enhancing productivity, the second wave is expected to transform job roles and the workforce structure. This shift indicates a deeper integration of AI technology in healthcare operations.

  • 01First wave of AI increased productivity in healthcare.
  • 02Second wave aims to restructure job roles.
  • 03AI will deeply integrate into healthcare operations.

Jul 13, 2026

Explore More Healthcare Insights

Read more expert perspectives from across Healthcare.

Browse Healthcare Hub

About the Expert

KS
Kevin Stevenson

For B2B teams

Your experts could be publishing here

Stories like this one run on content MarketScale captures from real practitioners. See how your team's expertise becomes coverage in Healthcare and beyond.

Book a 15-minute demo

Or call us. No forms required. We pick up. 214-945-2512